MS
RNTX

Maven Securities’s Rein Therapeutics RNTX Stock Holding History

Maven Securities’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,000
Closed -$700K – 1375
2021
Q1 		$700K Buy
+25,000
New +$857K 0.03% 533
2020
Q4 		– Sell
-4,250
Closed -$106K – 905
2020
Q3 		$106K Buy
4,250
+1,750
+70% +$41.2K 0.01% 577
2020
Q2 		$59K Buy
+2,500
New +$40.7K ﹤0.01% 511

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's RNTX Position: Q2 2021 in Review

Maven Securities sold out of Rein Therapeutics (RNTX) in Q2 2021, closing a stake of 25,000 shares — an estimated $700K sold.

Maven Securities first reported a position in RNTX in Q2 2020 and held it in 3 quarters. The position peaked at $700K in Q1 2021. 47 funds tracked by Wall St. Rank hold RNTX as of Q2 2021.

  • Maven Securities reported no remaining Rein Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 25,000 Rein Therapeutics shares in Q2 2021, an estimated $700K.
  • Maven Securities first reported a position in Rein Therapeutics in Q2 2020 and held it in 3 quarters.
  • Maven Securities's Rein Therapeutics position peaked at $700K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.